Missing or inadequate procedures for handling out of specification (OOS) situations and failure investigations are amongst the most frequently found deviations in warning letters from the U.S. Food and Drug Administration (FDA). While most companies do have procedures in place, these are not adequate—or are not followed.
Join pharmaceutical consultant Danielle DeLucy in this live webinar as she guides you through the entire process from detection of an out-of-specification result to informal and formal laboratory and batch investigations.
After attending this audio event, you will know the FDA’s requirements for handling OOS results, phase I and II lab and full-scale investigations, Out Of Trend (OOT) investigations, and common pitfalls during OOS investigations.
Here is a taste of what you will uncover:
Who Should Attend
Ask a question at the Q&A session following the live event and get advice unique to your situation, directly from our expert speaker.
- Casper E. Uldriks
Danielle DeLucy, MS, is owner of ASA Training and Consulting, LLC which provides Pharmaceutical and Biologics based companies with training and quality systems assistance in order to meet Regulatory compliance. Prior to this role, Danielle has been in the industry for 15 years serving in numerous Quality Management Roles, such as the Director of Product Quality, the oversight of Sterility Assurance practices and provided QA oversight of numerous...
More Events By The Speaker